Cecilia Pascual-Garrido
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Femoracetabular Impingement | 12 | 2025 | 47 | 5.770 |
Why?
| | Osteoarthritis, Hip | 11 | 2025 | 60 | 5.460 |
Why?
| | Cartilage, Articular | 17 | 2023 | 366 | 4.130 |
Why?
| | Hip Joint | 15 | 2023 | 187 | 2.670 |
Why?
| | Acetabulum | 12 | 2026 | 130 | 2.160 |
Why?
| | Cartilage Diseases | 6 | 2018 | 51 | 2.150 |
Why?
| | Hip Dislocation | 8 | 2026 | 65 | 2.110 |
Why?
| | Chondrocytes | 9 | 2025 | 241 | 2.050 |
Why?
| | Osteotomy | 9 | 2026 | 138 | 2.030 |
Why?
| | Arthroscopy | 13 | 2023 | 281 | 1.820 |
Why?
| | Femur Head | 7 | 2026 | 45 | 1.770 |
Why?
| | Hip Dislocation, Congenital | 7 | 2024 | 48 | 1.640 |
Why?
| | Knee Joint | 10 | 2017 | 453 | 1.290 |
Why?
| | Arthroplasty, Replacement, Hip | 6 | 2025 | 193 | 1.260 |
Why?
| | Epigenesis, Genetic | 3 | 2025 | 712 | 1.250 |
Why?
| | Osteoarthritis, Knee | 5 | 2018 | 291 | 1.230 |
Why?
| | Femur Head Necrosis | 2 | 2025 | 17 | 1.020 |
Why?
| | PPAR gamma | 2 | 2025 | 182 | 0.980 |
Why?
| | Osteochondritis Dissecans | 3 | 2013 | 17 | 0.980 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2025 | 38 | 0.870 |
Why?
| | Edema | 1 | 2025 | 131 | 0.840 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4580 | 0.730 |
Why?
| | Hip | 4 | 2023 | 61 | 0.730 |
Why?
| | Platelet-Rich Plasma | 3 | 2017 | 44 | 0.720 |
Why?
| | Femur | 3 | 2016 | 264 | 0.680 |
Why?
| | Hydrogels | 2 | 2018 | 708 | 0.650 |
Why?
| | Chondrogenesis | 2 | 2018 | 90 | 0.640 |
Why?
| | Models, Statistical | 1 | 2025 | 669 | 0.640 |
Why?
| | Bone Marrow Transplantation | 3 | 2018 | 301 | 0.620 |
Why?
| | Disease Progression | 7 | 2025 | 2867 | 0.620 |
Why?
| | Outcome Assessment (Health Care) | 2 | 2009 | 2 | 0.610 |
Why?
| | Biological Therapy | 2 | 2017 | 30 | 0.600 |
Why?
| | Transplantation, Autologous | 3 | 2016 | 306 | 0.590 |
Why?
| | Tissue Scaffolds | 2 | 2017 | 223 | 0.550 |
Why?
| | Hip Dysplasia, Canine | 1 | 2018 | 1 | 0.540 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 63 | 0.530 |
Why?
| | Torsion Abnormality | 2 | 2016 | 22 | 0.530 |
Why?
| | Tissue Engineering | 2 | 2018 | 442 | 0.510 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2019 | 196 | 0.510 |
Why?
| | Talus | 2 | 2016 | 20 | 0.510 |
Why?
| | Bone Marrow | 1 | 2018 | 310 | 0.490 |
Why?
| | Rabbits | 3 | 2025 | 651 | 0.490 |
Why?
| | Hemiarthroplasty | 1 | 2016 | 11 | 0.490 |
Why?
| | Orthopedic Procedures | 4 | 2016 | 260 | 0.480 |
Why?
| | Knee Prosthesis | 1 | 2016 | 31 | 0.470 |
Why?
| | Humans | 53 | 2026 | 146342 | 0.460 |
Why?
| | Osteoarthritis | 1 | 2018 | 206 | 0.460 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 190 | 0.460 |
Why?
| | Hip Prosthesis | 1 | 2016 | 43 | 0.460 |
Why?
| | Anterior Cruciate Ligament | 2 | 2013 | 103 | 0.440 |
Why?
| | Transcriptome | 1 | 2022 | 1068 | 0.440 |
Why?
| | Biocompatible Materials | 1 | 2018 | 432 | 0.420 |
Why?
| | Follow-Up Studies | 10 | 2026 | 5439 | 0.410 |
Why?
| | X-Ray Microtomography | 3 | 2025 | 117 | 0.410 |
Why?
| | Bone Malalignment | 1 | 2014 | 13 | 0.410 |
Why?
| | Biological Products | 1 | 2017 | 258 | 0.390 |
Why?
| | Adult | 25 | 2026 | 41087 | 0.380 |
Why?
| | Male | 30 | 2026 | 73396 | 0.370 |
Why?
| | Anterior Cruciate Ligament Reconstruction | 2 | 2013 | 195 | 0.370 |
Why?
| | Cell- and Tissue-Based Therapy | 3 | 2018 | 82 | 0.370 |
Why?
| | Forearm Injuries | 1 | 2011 | 7 | 0.350 |
Why?
| | Imaging, Three-Dimensional | 3 | 2025 | 582 | 0.330 |
Why?
| | Interleukin-1beta | 2 | 2025 | 397 | 0.320 |
Why?
| | Wound Healing | 4 | 2018 | 354 | 0.320 |
Why?
| | Female | 28 | 2026 | 79499 | 0.320 |
Why?
| | Tissue Survival | 1 | 2010 | 17 | 0.310 |
Why?
| | Injections, Intra-Articular | 3 | 2018 | 64 | 0.300 |
Why?
| | Patellofemoral Joint | 1 | 2009 | 9 | 0.300 |
Why?
| | Reoperation | 6 | 2026 | 645 | 0.300 |
Why?
| | Middle Aged | 16 | 2025 | 36619 | 0.300 |
Why?
| | Young Adult | 15 | 2026 | 14330 | 0.290 |
Why?
| | Range of Motion, Articular | 7 | 2024 | 446 | 0.270 |
Why?
| | Femur Neck | 2 | 2026 | 64 | 0.270 |
Why?
| | Wounds, Nonpenetrating | 1 | 2011 | 305 | 0.270 |
Why?
| | Cohort Studies | 7 | 2023 | 6077 | 0.260 |
Why?
| | Cells, Cultured | 3 | 2025 | 4118 | 0.260 |
Why?
| | Patient Reported Outcome Measures | 3 | 2021 | 516 | 0.250 |
Why?
| | Patient Satisfaction | 3 | 2018 | 706 | 0.240 |
Why?
| | Retrospective Studies | 13 | 2026 | 17438 | 0.240 |
Why?
| | Bone Marrow Cells | 2 | 2018 | 328 | 0.240 |
Why?
| | Animals | 10 | 2025 | 38107 | 0.240 |
Why?
| | Treatment Outcome | 10 | 2026 | 11821 | 0.230 |
Why?
| | Body Mass Index | 1 | 2014 | 2458 | 0.230 |
Why?
| | Arthralgia | 4 | 2024 | 66 | 0.230 |
Why?
| | Decompression, Surgical | 1 | 2025 | 115 | 0.210 |
Why?
| | Athletic Injuries | 1 | 2011 | 575 | 0.210 |
Why?
| | Adolescent | 12 | 2026 | 22557 | 0.210 |
Why?
| | Fractures, Stress | 1 | 2023 | 32 | 0.190 |
Why?
| | Bone-Patellar Tendon-Bone Grafting | 2 | 2013 | 15 | 0.190 |
Why?
| | Prognosis | 3 | 2025 | 4351 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2020 | 1818 | 0.180 |
Why?
| | Alcian Blue | 1 | 2022 | 1 | 0.180 |
Why?
| | Hematoxylin | 1 | 2022 | 9 | 0.180 |
Why?
| | Radiography | 4 | 2026 | 861 | 0.180 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 2113 | 0.170 |
Why?
| | Tendons | 2 | 2013 | 136 | 0.170 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3416 | 0.160 |
Why?
| | Fractures, Cartilage | 2 | 2010 | 7 | 0.160 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2020 | 25 | 0.160 |
Why?
| | Prospective Studies | 6 | 2025 | 8123 | 0.160 |
Why?
| | Injections | 2 | 2017 | 201 | 0.150 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 467 | 0.150 |
Why?
| | Arm | 1 | 2020 | 111 | 0.150 |
Why?
| | Contraindications, Procedure | 1 | 2019 | 14 | 0.140 |
Why?
| | Proof of Concept Study | 1 | 2018 | 90 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3926 | 0.130 |
Why?
| | Stereolithography | 1 | 2017 | 8 | 0.130 |
Why?
| | Aged | 6 | 2025 | 26432 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2019 | 426 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.130 |
Why?
| | Musculoskeletal Diseases | 1 | 2018 | 95 | 0.130 |
Why?
| | Gait | 1 | 2020 | 322 | 0.130 |
Why?
| | Databases, Factual | 2 | 2021 | 1493 | 0.120 |
Why?
| | Biomarkers | 2 | 2020 | 4340 | 0.120 |
Why?
| | Species Specificity | 1 | 2018 | 543 | 0.120 |
Why?
| | Printing, Three-Dimensional | 1 | 2017 | 102 | 0.120 |
Why?
| | Debridement | 2 | 2014 | 86 | 0.120 |
Why?
| | Dogs | 1 | 2018 | 517 | 0.120 |
Why?
| | Age Factors | 2 | 2014 | 3347 | 0.120 |
Why?
| | Athletes | 1 | 2020 | 432 | 0.120 |
Why?
| | Pain, Postoperative | 1 | 2015 | 1 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2016 | 124 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2016 | 126 | 0.110 |
Why?
| | Cartilage | 1 | 2016 | 198 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2786 | 0.100 |
Why?
| | Extracellular Matrix | 1 | 2018 | 565 | 0.100 |
Why?
| | Prosthesis Design | 1 | 2016 | 358 | 0.100 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 2014 | 61 | 0.100 |
Why?
| | Menisci, Tibial | 1 | 2014 | 79 | 0.100 |
Why?
| | Body Height | 1 | 2014 | 205 | 0.100 |
Why?
| | Stem Cells | 1 | 2017 | 613 | 0.100 |
Why?
| | Rotator Cuff | 1 | 2013 | 62 | 0.090 |
Why?
| | Signal Transduction | 2 | 2025 | 5246 | 0.090 |
Why?
| | Equipment Design | 1 | 2014 | 520 | 0.090 |
Why?
| | Allografts | 1 | 2013 | 151 | 0.090 |
Why?
| | Popliteal Vein | 1 | 2012 | 5 | 0.090 |
Why?
| | Posterior Cruciate Ligament | 1 | 2012 | 15 | 0.090 |
Why?
| | Popliteal Artery | 1 | 2012 | 60 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 189 | 0.080 |
Why?
| | Rupture | 1 | 2011 | 91 | 0.080 |
Why?
| | Biomechanical Phenomena | 3 | 2021 | 874 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2021 | 3034 | 0.080 |
Why?
| | Risk Assessment | 2 | 2019 | 3712 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2018 | 1982 | 0.080 |
Why?
| | Poloxamer | 1 | 2010 | 11 | 0.080 |
Why?
| | Intraoperative Complications | 1 | 2012 | 157 | 0.080 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2013 | 218 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 968 | 0.080 |
Why?
| | Sex Factors | 1 | 2016 | 2107 | 0.080 |
Why?
| | Surface-Active Agents | 1 | 2010 | 99 | 0.070 |
Why?
| | Mucous Membrane | 1 | 2010 | 130 | 0.070 |
Why?
| | Bone Transplantation | 1 | 2010 | 91 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2919 | 0.070 |
Why?
| | Vascular Surgical Procedures | 1 | 2012 | 352 | 0.070 |
Why?
| | Heart Arrest | 1 | 2012 | 411 | 0.060 |
Why?
| | Child | 4 | 2024 | 22693 | 0.060 |
Why?
| | Postoperative Care | 1 | 2009 | 301 | 0.060 |
Why?
| | Surgical Procedures, Operative | 1 | 2009 | 307 | 0.060 |
Why?
| | Recovery of Function | 2 | 2021 | 725 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8391 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2010 | 3647 | 0.040 |
Why?
| | Fantasy | 1 | 2018 | 3 | 0.040 |
Why?
| | Veterinary Medicine | 1 | 2018 | 12 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2018 | 51 | 0.030 |
Why?
| | Regenerative Medicine | 1 | 2018 | 48 | 0.030 |
Why?
| | Risk Factors | 2 | 2024 | 10921 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 3017 | 0.030 |
Why?
| | Polymerization | 1 | 2017 | 129 | 0.030 |
Why?
| | Rotation | 1 | 2016 | 124 | 0.030 |
Why?
| | Preoperative Period | 1 | 2016 | 157 | 0.030 |
Why?
| | Orthopedics | 1 | 2018 | 182 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2019 | 442 | 0.030 |
Why?
| | Cattle | 1 | 2017 | 940 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1331 | 0.030 |
Why?
| | Psychometrics | 1 | 2019 | 712 | 0.030 |
Why?
| | Light | 1 | 2017 | 401 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1271 | 0.020 |
Why?
| | Linear Models | 1 | 2016 | 857 | 0.020 |
Why?
| | Tibial Meniscus Injuries | 1 | 2014 | 63 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 197 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2016 | 1298 | 0.020 |
Why?
| | Preoperative Care | 1 | 2016 | 396 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2017 | 650 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1543 | 0.020 |
Why?
| | Osteogenesis | 1 | 2013 | 205 | 0.020 |
Why?
| | Pulmonary Edema | 1 | 2012 | 105 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2010 | 84 | 0.020 |
Why?
| | Intraoperative Care | 1 | 2010 | 68 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 183 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7109 | 0.020 |
Why?
| | Rare Diseases | 1 | 2010 | 117 | 0.020 |
Why?
| | Bone Density | 1 | 2013 | 494 | 0.020 |
Why?
| | Ankle Injuries | 1 | 2010 | 67 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 263 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 245 | 0.020 |
Why?
| | Ankle Joint | 1 | 2010 | 135 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2537 | 0.020 |
Why?
| | Pain Measurement | 1 | 2010 | 573 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2921 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2010 | 823 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3200 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1712 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2010 | 784 | 0.010 |
Why?
| | Pyridines | 1 | 2010 | 610 | 0.010 |
Why?
| | Diet | 1 | 2013 | 1273 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5586 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5899 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2439 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1849 | 0.010 |
Why?
|
|
Pascual-Garrido's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|